BioSpace News Archive

AveXis, a Novartis company, today announced a one-time infusion of Zolgensma® (onasemnogene abeparvovec-xioi) showed rapid, significant and clinically meaningful therapeutic benefit in patients with spinal muscular atrophy (SMA) across a range of studies, including in patients treated presymptomatically, and sustained durability in patients now up to five years post-dosing and some patients more than five years of age.

- Proof of concept for both agonistic and ligand-blocking TNFR2 targeting antibodies - Both antibodies showed significant antitumor activity in several immunocompetent models - TNFR2 targeting antibodies induce tumor-specific T cell responses, regress large tumors and synergize with anti-PD-1 - Phase I clinical trial with BI-1808 expected to start before the end of 2020 - Data on BI-1808 and BI-1910 presented at AACR Virtual Session II

Collaboration between the transplant community, industry, and regulatory agencies develops biomarker aimed to streamline the development of novel therapies intended to improve long-term outcomes for kidney transplant recipients.

Public health law developed as a response to potential bioterrorism as with weaponized smallpox.

Conformis, Inc. (NASDAQ:CFMS) today announced 510(k) clearance by the U.S. Food and Drug Administration of the Company’s next generation iTotal ® Identity PS Knee System. The iTotal ® Identity PS Knee System uses proprietary advanced imaging and design software, to deliver a patient-specific, pre-operative surgical plan with a comprehensive set of iJig instruments and patient-matched implants. Updates to this system include stem extensio

Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MATN) announces that both Golden Mountain Partners (GMP) and Mateon have fulfilled all the obligations under the Research and Services Agreement (the “Agreement”) entered on February 3, 2020 and modified on March 22, 2020.

Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced that 36 subjects have been enrolled in the phase 2 clinical trial evaluating Ad-RTS-hIL-12 with veledimex (Controlled IL-12) in combination with the PD-1 inhibitor Libtayo ® (cemiplimab-rwlc) for the treatment of recurrent or progressive glioblastoma (rGBM) in adults. Subjects in this multi-center trial were enrolled from seven hospitals specializing in the treatme

Patients who undergo more focused, enhanced milestone-based rehabilitation after anterior cruciate ligament surgery experience better outcomes in the long run at a lower cost to the healthcare system, researchers at Hospital for Special Surgery in New York City have found.

Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental biologics license application (sBLA) to expand the BOTOX ® prescribing informati

First Virtual Panel Features Renal Health Care Professionals Sharing Best Practices for Chronic Kidney Disease Patient Care in the COVID-19 Environment